Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third quarter financial results. Natco Pharma Ltd. shares tanked during the ...

Image Source : PIXABAY The counter opened gap down with a loss of 18.96 per cent. NATCO Pharma share price: The shares of NATCO Pharma Ltd, a constituent of BSE 500, tanked 20 per cent on Thursday ...

Shares of NATCO Pharma tumbled another 10% in intra-day trade on Friday, February 14, extending its slide to the sixth straight session. The stock had tumbled 20% on Thursday as well following the ...

Natco Pharma corrected a significant 32 per cent last week. The stock declined 20 per cent on Thursday and further corrected 9 per cent on Friday, dragged by the company’s weak Q3FY25 results.

The pharmaceutical firm’s consolidated revenue from operations fell to ₹474.8 crore in Q3 FY2025, down from ₹758.6 crore in the year-ago period, reflecting a 37.4 percent decrease in ...

The company had posted a consolidated net profit of Rs 212.7 crore in the third quarter of the previous fiscal year, NATCO Pharma said in a regulatory filing. Consolidated revenue from operations in ...

Natco Pharma Ltd has received final approval from the USFDA to market Bosentan 32mg tablets. This drug, Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension (PAH).

Natco Pharma has received U.S. Food and Drug Administration final approval for Bosentan tablets for oral suspension, 32mg, its generic version of Actelion Pharmaceuticals US Inc.’s pulmonary ...

Global pharma major Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco), announced that they have received an approval from the United States Food and Drug Administration (FDA) ...

Shares of Natco Pharma Ltd fell sharply in Thursday's trade after the company reported a 38 per cent, year-on-year (YoY), decline in its December 2024 quarter (Q3 FY25) consolidated net profit.

Shares of Natco Pharma were battered in trade on February 13, plunging as much as 18.5 percent as investors dumped the stock following its disappointing Q3 earnings performance. The drugmaker's ...